Phenotype of glutathione S-transferase Mu (GSTM1) and susceptibility to malignant melanoma

A Lafuente1, R Molina2, J Palou3, T Castel1, A Moral4, M Trias4 and the MMM group*

1Institut de Salut Pública, Universitat de Barcelona; 2Clinical Chemistry Department; Departments of 3Dermatology and 4Surgery, Hospital Clinic, Barcelona; Hospital Clinic, C/Villarroel 170, 08036 Barcelona, Spain.

Summary The isoenzyme Mu of glutathione S-transferase (GSTM1) is dominantly inherited, and the prevalence of this isoenzyme in the population is about 60%. The lack of GSTM1 has been linked with cancer risk. The frequency of the phenotypes of this isoenzyme in melanoma (MM) patients (n = 197) is reported here. A significantly higher proportion of individuals in the control group (n = 147) had measurable GSTM1 than MM patients (59.1% vs 42%, P = 0.002); there was a higher proportion of positive phenotypes in general among women than among men. Odds ratio analysis indicated that individuals with this polymorphic variant have an approximately 2-fold risk of developing these cancers. GSTM1 phenotype distribution depends on age, smoking habit and tumour pathology. A group of MM patients with dysplastic naevi was also studied.

Keywords: free radicals; DNA repair; skin carcinogenesis; dysplastic naevi

Epidemiological studies gathered over the last decade indicate that malignant melanoma (MM) in humans is related to both sun exposure habits and host factors. Ultraviolet (UV) irradiation leads to reactive oxygen species (ROS) attack on target molecules such as lipids, proteins and nucleic acids. Unrepaired damage to DNA appears to play a central role in these carcinogenesis processes (Longstreth et al., 1992). As a host genetic factor, dysplastic naevi (DN), which are relatively distinct melanocytic lesions, can be precursors of melanoma, and responsible for the tendency of melanoma to run in families. Metabolic factors such as the isoenzyme Mu of glutathione S-transferase (GSTM1) should also be considered. GSTM1 has polymorphic expression, and about half the population from various racial groups lack it (Hussey et al., 1986). The enzyme detoxifies various carcinogenic electrophiles including epoxides, and it has therefore been attributed a protective role against neoplasias associated with smoking. Indeed, a major susceptibility to lung (Seidegard et al., 1986), bladder and larynx cancer (Lafuente et al., 1993) has been shown among smokers lacking GSTM1.

When ROS damage DNA, the derived residues, which are cytotoxic and cytostatic, are also substrates of GSTM1, suggesting that these isoforms also have a role in the DNA repair system (Ketterer and Meyer, 1989).

We therefore designed a study to determine whether GSTM1 deficiency may confer susceptibility to malignant melanoma (MM) on the basis of the antioxidant properties of this isoenzyme against UV-derived ROS.

Materials and methods

A total of 197 white melanoma patients were recruited at the Dermatology Department at the Hospital Clinic of Barcelona in 1993. Ninety-three patients were men (mean age 53.0 ± 19.0) and 104 were women (mean age 51.06 ± 16.4).

Skin pigmentation was evaluated by phototypes (Beitner et al., 1990) which include type I (5%), type II (29%), type III (49%) and type IV (17%). All had historically proven malignant melanoma and none had received prior chemotherapy or radiotherapy. A total of 147 unrelated white control individuals without clinical or histological evidence of cancer or inflammatory pathology were recruited from the Surgery Department (82 men, mean age 51.6 ± 16.0; and 65 women, mean age 52.01 ± 19.8). Of the MM patients, 14 had dysplastic naevi and were studied as a separate group for which MM- and melanoma-free relatives were used as controls (n = 14).

Leucocytic GSTM1 was measured in whole blood samples with an enzyme-linked immunosassay (ELISA) using affinity-purified rabbit polyclonal antibody to human GSTM1 (MUKIT, Biotrin, Dublin, Ireland). Fifty microlitres of haemolysed blood samples was mixed with 125 μl of phosphate-buffered saline (PBS) including 1% bovine serum albumin (BSA) and 25 μl of Triton X-100. The remaining procedure was as specified by the Mukit technical bulletin, with the modification introduced by Brockmoller et al. (1993) for the quantitative calibration of all assays: one batch of electrophoretically pure GST class μ protein (from Biotrin) is added to one batch of venous blood (in PBS, 1:1) from a GSTM1-deficient individual.

Standard curves were made up between 0.010 and 50 μg ml⁻¹ in whole blood. Individuals with enzyme levels below 1 μg ml⁻¹ were considered to be deficient in GSTM1. The mean of GSTM1 cross-reacting proteins for negative individuals was 0.123 μg ml⁻¹.

Leucocyte and differential counts were normal in all subjects included.

Immunohistochemistry studies were performed with purified rabbit polyclonal antibody to GSTM1 (BioGenex, San Ramon, CA, USA). The rest of the procedure for visualisation of antibody-reacting regions was performed using the biotin–streptavidin–alkaline phosphatase method (Multilink, BioGenex) with fast red chromogen for visualisation.

Odds ratios and confidence intervals (CIs) were used to analyse the frequencies of phenotypes; the corresponding χ² values were calculated.

Results

Data show a bimodal distribution of GSTM1 content, positioning the antimode at 1 μg ml⁻¹, thus confirming the previously established antimode described by Brockmoller et al. (1993). The mean GSTM1 content for positive controls was 3.16 ± 1.33 μg ml⁻¹ or 1.93 ± 1.14 μg/10⁻⁶ lymphocytes
Table I  Proportion of individuals expressing GSTM1 with and without melanoma

|                  | Melanoma | No melanoma | OR     | 95% CI | P     |
|------------------|----------|-------------|--------|--------|-------|
| Men              | 34/89 (0.382)* | 45/82 (0.548) | 1.96   | 1.35-2.56 | 0.02  |
| Women            | 43/94 (0.457) | 42/65 (0.646) | 2.1    | 1.45-2.74 | 0.01  |
| Men and women    | 77/183 (0.420) | 87/147 (0.591) | 1.99   | 1.56-2.41 | 0.002 |

*Number with GSTM1/total number examined (ratio of individuals with GSTM1).

Table II  Proportion of melanoma patients expressing GSTM1 in subgroups* based on tumour characteristics

| Histological type | Women | Men | Women and men |
|-------------------|-------|-----|---------------|
| SSM               | 32/69 (0.463)* | 18/50 (0.360) | 50/119 (0.420) |
| LMM               | 3/7 (0.428) | 2/6 (0.333) | 5/13 (0.384) |
| ALM               | 3/5 (0.600) | 4/8 (0.500) | 7/13 (0.538) |
| NM                | 4/15 (0.266) | 6/18 (0.333) | 10/33 (0.303) |
| TU                | 1/2 (0.500) | 4/7 (0.571) | 5/9 (0.555) |

| Clark classification | Women | Men | Women and men |
|----------------------|-------|-----|---------------|
| Grade I              | 7/14 (0.500) | 3/5 (0.600) | 10/19 (0.526) |
| Grade II             | 8/19 (0.421) | 6/13 (0.500) | 14/32 (0.437) |
| Grade III            | 21/44 (0.477) | 17/46 (0.369) | 38/90 (0.422) |
| Grade IV–V           | 8/20 (0.400) | 7/24 (0.291) | 15/44 (0.340) |

| Breslow index (mm) | Women | Men | Women and men |
|-------------------|-------|-----|---------------|
| <1.5              | 35/68 (0.514) | 22/57 (0.385) | 57/125 (0.456) |
| ≥1.5              | 9/26 (0.346) | 10/25 (0.400) | 19/51 (0.372) |

*Subgroups include DN-MM patients and exclude some cases in which it was not possible to obtain this information. *SSM, superficial spreading melanoma; LMM, lentigo maligna melanoma; ALM, acral lentiginous melanoma; NM, nodular melanoma; TU, type unclassified. *Number with GSTM1/total number examined (ratio of individuals with GSTM1).

...and for MM patients 3.37 ± 1.02 µg ml⁻¹ or 2.13 ± 1 µg 10⁻⁶ lymphocytes.

A significantly higher proportion of the control individuals had GSTM1 (59.1%) than melanoma patients (42%; χ² test, P = 0.002). When subgroups by sex were considered, proportions were maintained, although more individuals with positive phenotype were found among women in both groups. The overall odds ratio calculated was 1.99 (95% CI 1.56-2.41) (Table I).

Despite the limited number of cases, the frequency of positive GSTM1 was lower in DN-MM patients (35.7%), but also in DN controls (42.8%). In subgroups based on the skin phenotype, smoking habit or age at diagnosis, proportions showed no modifications. The distribution of GSTM1 based on histological subtypes of MM showed a trend towards a more common null phenotype in nodular melanoma than in superficial spreading melanoma (the most frequent subtypes), especially in women. Subgroups according to the depth of the tumour penetration show that the incidence of the null phenotype is higher when disease presents in a more aggressive form (grade IV–V, Breslow ≥1.5 mm) (Table II).

No difference in GSTM1 content in positive patients was found between any of the subgroups established.

Immunohistological studies on four of the eight patients

Figure 1  (a) GSTM1 showing staining of normal melanocytes in the basal layer, leaving the rest of epidermis practically unstained (×330). (b) GSTM1 showing moderate staining in MM cells (×165).
examined revealed that the antibody to GSTM1 stained the normal melanocytes strongly (in the basal layer), whereas the remaining epidermal cells stained weakly. Cytoplasms and nuclei in melanoma stained moderately (Figure 1). One hundred per cent correlation was found with ELISA blood results.

Discussion

Excessive UV irradiation, with consequent ROS attack on target molecules such as DNA, appears to be one of the major causes of melanoma. GSTM1 may be important in the repair of DNA since it is present in the normal melanocytes in both cytoplasms and nuclei, and because it may efficiently detoxify peroxides arising in DNA (Ketterer and Meyer, 1989).

Various authors have reported that GSTM1 is almost non-existent in human epidermis (Blackler et al., 1991; Campbell et al., 1991; Raza et al., 1991; Singhath et al., 1993). Minimal amounts of the Mu class GSTs are present in human skin samples, as shown by Western blot analysis or immunohistological staining in the human epidermis, where most cells are keratinocytes. Hence, the risk conferred by the presence or absence of GSTM1 in keratinocytes may also be minimal. However, in melanocytes the opposite is true. Normal melanocytes presented positive GSTM1 staining by immunohistological techniques in the study by Campbell et al. (1991), and this was also confirmed here, which suggests that this isoenzyme is important to the host defence of these cells.

GSTM1 deficiency has been studied in relation to lung (Seidegard et al., 1986), bladder and larynx cancer (Lafuente et al., 1993) and in individuals with multiple skin cancers (Heagerty et al., 1994), but this is the first time that this deficiency has been related to melanoma as single tumour. Our results confirm the importance of phase II enzymes such as GSTM1. Individuals with genetic absence of this isoenzyme appear to be more susceptible to these neoplasms. It also seems that these neoplasms appear in a more aggressive form, since certain negative clinical aspects, such as age at diagnosis, histological types and, especially, the depth of the tumour penetration, tend to depend on the presence of this isoenzyme (Lafuente et al., 1993).

Epidemiological studies suggest that host factors such as fair complexion and a tendency to sunburn rather than tan could be aetiopathogenic factors in malignant melanoma. The distribution of phototypes in MM patients is similar to distribution reported elsewhere (Elwood et al., 1986). However, compared with metabolic risk factors, skin phototypes seem to be independent of GSTM1 phenotype.

Smoking has also been suspected to be related to MM risk (Aubry and McGibbon, 1985); in fact, electroplihies from tobacco smoke could increase the toxicity of ROS, as has been extensively proposed in the literature (Kensler and Trush, 1985; Trush and Kessler, 1991). However, in contrast to what is observed in other tumours (Seidegard et al., 1986; Lafuente et al., 1993), the distribution of GSTM1 phenotypes is similar in smokers and in non-smokers, suggesting that in this case GSTM1 protection is not related to tobacco smoke exposure.

Therefore, it can be concluded that the protective role of GSTM1 operates even in neoplasms that have no direct relationship with tobacco smoke exposure. This provides indirect evidence of the considerable importance of GSTM1 in antioxidant defence, and in the DNA repair system.

Abbreviations:
DN, dysplastic naevi; GSTM1, glutathione S-transferase Mu; MM, malignant melanoma; ROS, reactive oxygen species.

Acknowledgements

This work was financed by the Ministry of Health (FIS 93/0028-02). We thank Gabriel Miguel, technician-fellow from CIRIT, for his excellent technical assistance and the Language Advisory Service at the University of Barcelona for correcting the English manuscript.

References

AUBRY F AND MCGIBBON B. (1985). Risk factors of squamous cell carcinoma of the skin. Cancer, 55, 907–911.

BEITNER H, MORELL SE, RINGBERG U, WINNERSTEN G AND MATTSON B. (1990). Malignant melanoma: aetiological importance of individual pigmentation and sun exposure. Br. J. Dermatol., 122, 43–51.

BLACKER KL, OLSON E, VESSEY DA AND BOYER TD. (1991). Characterization of glutathione S-transferase in cultured human keratinocytes. J. Invest. Dermatol., 97, 442–446.

BROCKMÖLLER J, KERB R, DRAKOULIS N, NITZ M AND ROOTS I. (1993). Genotype and phenotype of glutathione S-transferase class µ isoenzymes µ and φ in lung cancer patients and controls. Cancer Res., 53, 1004–1011.

CAMELL JAH, CORRIGALL AV, GUY A AND KIRSCH RE. (1991). Immunohistological localization of alpha, mu and pi class glutathione S-transferase in human tissues. Cancer, 67, 1608–1613.

ELWOOD JM, WILLIAMSON C AND STAPLETON PJ. (1986). Malignant melanoma in relation to moles, pigmentation, and exposure to fluorescent and other lighting sources. Br. J. Cancer, 53, 65–74.

HEAGERTY AHM, FITZGERALD D, SMITH A, BOWERS B, JONES P, FRYER AA, ZHAO L, AL-LEDERSEA J AND STRANGE RC. (1994). Glutathione S-transferase GSTM1 phenotypes and protection against cutaneous tumours. Lancet, 343, 266–268.

HUSSEY AJ, STOCKMAN PK, BECKETT GJ AND HAYES JD. (1986). Variations in the glutathione S-transferase subunits expressed in human livers. Biochim. Biophys. Acta, 874, 1–12.

KESLER TW AND TRUSH MA. (1985). Oxygen free radicals in chemical carcinogenesis. In Pathological States, Vol. III, Oberley LW (eds) pp 191–236. CRC Press: Boca Raton, FL.

KETTERER B AND MEYER DJ. (1989). Glutathione transferases: a possible role in the detoxication and repair of DNA and lipid hydroperoxides. Mutat. Res., 214, 33–40.

LAFUENTE A, PUJOL F, CARRETERO P, PEREZ VILLA J AND CUCHI A. (1993). Human glutathione S-transferase p (GSTM) deficiency as a marker for the susceptibility to bladder and larynx cancer among smokers. Cancer Lett., 68, 49–54.

LONGSTRETH JD, LEA CS AND KRIKPE ML. (1992). Ultraviolet radiation and other putative causes of melanoma. In Cutaneous Melanoma pp. 46–58. JB Lippincott: Philadelphia.

RAHA Z, AWASTHI YC, ZAIM MT, ECKERT RL AND MUKHTAR H. (1991). Glutathione S-transferases in human and rodent skin: multiple forms and species-specific expression. J. Invest. Dermatol., 96, 463–467.

SEIDEGARD J, PERO RW, MILLER DG AND BEATTIE EJ. (1986). A glutathione transferase in human leukocytes as a marker for the susceptibility to lung cancer. Carcinogenesis, 7, 751–753.

SINGHAL SS, SAXENA M, AWASTHI S, MUKHTAR H, ZAIDI SIA, AHMAD H AND AWASTHI YC. (1993). Glutathione S-transferases of human skin: qualitative and quantitative differences in men and women. Biochim. Biophys. Acta, 1163, 266–272.

TRUSH MA AND KENSLER TW. (1991). An overview of the relationship between oxidative stress and chemical carcinogenesis. Free Radicals Biol. Med., 10, 201–209.